Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Caliway Biopharmaceuticals Co., Ltd. clinical trials
The registry lists 16 studies whose lead sponsor is Caliway Biopharmaceuticals Co., Ltd.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Caliway Biopharmaceuticals Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Caliway Biopharmaceuticals Co., Ltd..
- Caliway Biopharmaceuticals Co., Ltd.16 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 16 of 16.
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )Not yet recruitingNCT07526974Phase 3
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatNot yet recruitingNCT07608757Phase 2
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatRecruitingNCT07608770Phase 2
- A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous FatRecruitingNCT07140939Phase 3
- A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)Not yet recruitingNCT07733947Phase 3
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)CompletedNCT05632926Phase 2
- A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease LipomasCompletedNCT06303570Phase 2
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)CompletedNCT05836779Phase 2
- A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy VolunteersCompletedNCT05234736Phase 2
- A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.CompletedNCT06005441Phase 2
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)CompletedNCT04575467Phase 2
- A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous FatCompletedNCT05736107Phase 2
- A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)CompletedNCT04897412Phase 2
- A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease LipomasCompletedNCT05387733Phase 2
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous FatCompletedNCT04698642Phase 2
- A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy VolunteersCompletedNCT04699669Phase 1